Publications
The list below provides an overview of selected publications in English. The full list of publications linked to the RENIS project is available in the Czech version of this website.
- Büchler T, Poprach A, Bortlíček Z, Lakomý R, Chloupková R, Vyzula R, Zemanová M, Kopečková K, Svoboda M, Slabý O, Kiss I, Studentová H, Hornová J, Fiala O, Kopecký J, Fínek J, Dušek L, Melichar B. Outcomes of patients with long-term treatment response to vascular endothelial growth factor-targeted therapy for metastatic renal cell cancer. Clinical Genitourinary Cancer 2017; 15(6): e1047-e1053.
- Lakomý R, Poprach A, Bortlíček Z, Melichar B, Chloupková R, Vyzula R, Zemanová M, Kopečková K, Svoboda M, Slabý O, Kiss I, Študentová H, Juráček J, Fiala O, Kopecký J, Fínek J, Dušek L, Hejduk K, Büchler T. Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. BMC Cancer 2017; 17: 880.
- Büchler T, Bortlíček Z, Poprach A, Pavlík T, Veškrnová V, Honzírková M, Zemanová M, Fiala O, Kubáčková K, Slabý O, Svoboda M, Vyzula R, Dušek L, Melichar B. Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis. European Urology 2016; 70(3): 469-475.
- Poprach A, Lakomý R, Bortlíček Z, Melichar B, Pavlík T, Slabý O, Vyzula R, Svoboda M, Kiss I, Študentová H, Zemanová M, Fiala O, Kubáčková K, Dušek L, Hornová J, Büchler T. Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. Drugs & Aging 2016; 33(9): 655-663.
- Kubáčková K, Bortlíček Z, Pavlík T, Melichar B, Linke Z, Pokorná P, Vyzula R, Prausová J, Büchler T. Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry. Targeted Oncology 2015; 10(3): 385–392.
- Poprach A, Bortlíček Z, Melichar B, Lakomý R, Svoboda M, Kiss I, Zemanová M, Fiala O, Kubáčková K, Coufal O, Pavlík T, Dušek L, Vyzula R, Buchler T. Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency. European Journal of Cancer 2015; 51(4): 507–513.
- Büchler T, Bortlíček Z, Poprach A, Kubáčková K, Kiss I, Zemanová M, Fiala O, Dušek L, Vyzula R, Melichar B. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. Urologic Oncology: Seminars and Original Investigations 2014; 32(5): 569–575.
- Poprach A, Pavlík T, Melichar B, Kubáčková K, Bortlíček Z, Svoboda M, Lakomý R, Vyzula R, Kiss I, Dušek L, Büchler T. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. Urologic Oncology: Seminars and Original Investigations 2014; 32(4): 488–495.
- Büchler T, Pavlík T, Bortlíček Z, Poprach A, Vyzula R, Abrahámová J, Melichar B. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Medical Oncology 2012; 29(5): 3321–3324.
- Poprach A, Bortlíček Z, Büchler T, Melichar B, Lakomý R, Vyzula R, Brabec P, Svoboda M, Dušek L, Gregor J. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Medical Oncology 2012; 29(5): 3314–3320.
- Poprach A, Pavlík T, Melichar B, Puzanov I, Dušek L, Bortlíček Z, Vyzula R, Abrahámová J, Büchler T. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Annals of Oncology 2012; 23(12): 3137–3143.
- Büchler T, Klapka R, Melichar B, Brabec P, Dušek L, Vyzula R, Abrahámová J. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry. Annals of Oncology 2012, 23(2): 395–401.
